ABSTRACT
Cervical cancer (CxCa) incidence remains high in China, when compared to countries with well-established cervical screening and treatment programs. 1 According to recently published data, nearly 100,000 new CxCa cases may be diagnosed nationwide in China each year, with annual mortality estimates of around 30,000. 2 Cervical screening in China remains largely limited to occasional opportunistic screening in urban centers, with only more recently initiated efforts to extend screening into rural areas. 3 The Papanicolaou (Pap) test has been the most successful cancer screening test in medical history 4 and has helped achieve lower CxCa incidence and mortality rates in many countries that have established effective cervical screening programs. 5 Over the last 15 to 20 years, human papillomavirus (HPV) testing has been added, both as an adjunctive cervical screening test 6, 7 and more recently as a potential stand-alone primary screening test. 8 Out of more than 200 identified HPV genotypes, 14 genotypes are commonly classified as carcinogenic, 9 and it is persistent infections with these high-risk (hr) genotypes that is now considered the predominant cause of CxCa and its potentially progressive precursor lesions. 10, 11 Accordingly, repeated testing for persistence of specific carcinogenic genotypes is considered to have potential utility in cervical screening risk stratification. 10 The prevalence of hrHPV infection varies substantially between countries and has been found to correlate well with overall CxCa risk in the corresponding populations, particularly among middle-aged women. [12] [13] [14] In contrast, international variation in HPV genotype distribution has been found to be limited among women with normal or lower-grade (atypical squamous cells undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL] ) cytologic findings and has been more notable among women with invasive CxCas, high-grade squamous intraepithelial lesion (HSIL) cytology, or histopathologic cervical intraepithelial neoplasia grade 2/3 (CIN 2/3) diagnoses. 15 International differences in HPV genotype distribution have been considered potentially significant in regional planning for possible increased utilization of extended HPV genotype testing in screening programs or in future HPV vaccine development. 16 Given the limited available data on HPV genotype distribution and correlative cytology findings in women subsequently diagnosed with clinically significant "precancer" and CxCa diagnoses, we decided to analyze available data from a large cohort of women at a university women's hospital in southwestern China with histopathologic CIN 2/3 and CxCa diagnoses and prior cytology and extended HPV genotyping results.
Materials and Methods

Patient Selection
Histopathologic diagnoses of CIN 2/3 and CxCa reported between January 2012 and June 2016 were identified in the laboratory information system (LIS) of the Department of Pathology, West China Second University Hospital of Sichuan University (WCSUH). WCSUH is the second largest women's hospital in China. Most patients were from Sichuan province and other adjacent areas, including Yunnan and Guizhou provinces and the Tibet Autonomous Region. Histopathologic diagnoses were reported on samples including endocervical curettage specimens, cervical biopsies, cervical diagnostic excisional specimens utilizing loop electrosurgical excision procedures or cold-knife conization, and hysterectomy specimens. HPV and Pap tests were ordered by gynecologists at WCSUH on the basis of clinical judgment and patient preference. Histopathologic diagnoses, prior HPV test results, and available prior Pap test results at WCSUH were recorded. Only cases with documented prior HPV test results within 6 months before histopathologic diagnoses of CIN 2/3 or CxCa were included in this study.
HPV Testing
HPV testing was performed in the WCSUH Department of Pathology by one of two extended HPV genotyping test methods: (1) 
Pap Tests
Pap tests were performed in the WCSUH Department of Pathology using one of two methods: (1) the ThinPrep Pap test (TPPT) (Hologic, Bedford, MA) or (2) the SurePath Pap test (BD Diagnostics, Franklin Lakes, NJ). Samples were collected by gynecologists and slides were prepared according to the manufacturers' specifications. All Pap tests were reported using The Bethesda System 2001 terminology. All Pap tests were screened, interpreted, and reported by a team of WCSUH gynecological pathologists, as cytotechnologist is not currently a recognized profession in China. The specimens for Pap and HPV testing were collected in two separate vials.
Statistical Analysis
The Pearson χ 2 test was used for statistical analysis and conducted with IBM SPSS statistics software (version 19.0; IBM Corp, Armonk, NY). The Fisher exact test was applied to analyze the data when smaller study sets were being examined. A P value of less than .05 was considered to be statistically significant.
Results
Study Patients
A total of 2771 cases with histopathologic diagnoses of CIN 2/3 and 370 cases with diagnoses of CxCa and extended HPV genotyping test results within the prior 6 months were identified in the hospital database and included in the current study. 
HPV Test Results
The average time period between HPV testing and histopathologic CIN 2/3 diagnoses was 0.7 months (range, 0.1-6 months) and 0.4 months (range, 0.1-6 month) for CxCa cases. The majority of cotested patients in this study had HPV and Pap testing during their initial clinical visits to WCSUH.
Extended HPV genotype testing was performed on 1,338 patient samples using the YanengBIO method and on 1,433 patient samples using the Tellgen method In 370 cases of CxCa, the overall hrHPV-positive rate was 88.4% (Table 1) . Of the CxCa cases, 11.6% had negative hrHPV test results only a short time before histopathologic diagnosis. Patients with cervical adenocarcinomas and adenosquamous carcinomas had a significantly lower hrHPV-positive rate of 77.5% (31/40), compared to the 89.6% HPV-positive rate in cases with squamous cell carcinoma (P = .0253). hrHPV-positive rates showed no significant differences between the extended HPV genotype testing methods for the cases of CxCa (data not shown).
Numbers of recorded hrHPV, lrHPV, mixed type hrHPV, and lrHPV infections for CIN 2/3 cases are shown in Table 2 In 370 cases of CxCa, a single hrHPV genotype with or without lrHPV was reported in 296 of 327 hrHPV-positive cases (90.5%), and in 80% of all CxCa cases ❚Table 3❚. lrHPV infection was reported in only 11 of 370 cases (3.0%). No case with lrHPV infection alone was reported among these 370 CxCas.
The most commonly detected hrHPV genotype in CIN 2/3 cases was HPV 16 19 HPV 16 or 18 infections were detected in our Chinese study population in 77% of samples collected at or less than 6 months before 370 histopathologic CxCa diagnoses (Table 5 ). HPV 16 infections were by far the most prevalent, detected in 70% of CxCa cases. The next two most commonly detected HPV genotypes worldwide in CxCa have been HPV 58 (4.7%) and 33 (4.6%), and also in our study HPV 58 (5.7%) and 33 (4.1%) were the third and fourth most commonly detected genotypes. However, our finding of HPV 59 as the fifth most commonly detected (1.9%) genotype differed from other worldwide datasets in which HPV 59 was not among the eight most common genotypes detected in CxCa. 19, 20 In our study, both HPV 53 and 59 were detected in seven of 370 CxCa cases (1.9%).
It has been suggested that the genotype distribution of HPV in CxCas in Chinese populations may differ somewhat from that found elsewhere. 16 ,21,22 HPV 52 was detected in 5% to 10% of CxCa in each of the three other largest published Chinese studies, 16, 21, 22 compared to only 1.4% of CxCa cases in our study population. Other studies on HPV genotyping data from China have reported especially high rates of HPV 52 detection in the general Chinese screening population. 17 HPV 52 was also detected in 5% to 10% of 392 CxCas collected elsewhere in Asia, from Malaysia, Vietnam, Singapore, South Korea, and the Philippines. 23 In our study, and also in the other large previously cited Chinese studies, 16, 21, 22 HPV 45 was detected in less than 1% of CxCas, whereas in all other regions of the world, including western and central Asia, 19, 23 HPV 45 has been among the third to the fifth most commonly detected HPV genotype in CxCas. These observations underscore the significant variations that may occur in different populations.
A number of studies have now documented that the HPV genotype distribution in CxCa cases differs significantly from the HPV genotype distribution in high-grade intraepithelial lesions (presumed "precancers") in the same populations. [24] [25] [26] [27] Underrepresentation of HPV 18/45 in intraepithelial lesions relative to CxCas has been linked to occult pathology and in particular difficult-to-diagnose cervical glandular neoplasms. 25 populations has also been attributed in part to greater potential of these genotypes for rapid neoplastic transformation. 26 In our study the prevalence of five high-risk HPV genotypes were significantly higher in CxCa cases than in CIN 2/3 cases. HPV 16/18/59/39/45 were 1.5/1.5/1.5/1.4/1.6 times, respectively, more frequently detected in association with CxCa cases than with CIN 2/3 cases. Findings that most hrHPV genotypes were more prevalent in association with CIN 2/3 than with CxCa may well be related to the often nonprogressive character of many highgrade intraepithelial lesions. 28 In fact, detection of nonprogressive intraepithelial lesions have been estimated in some clinical trials by measuring the rate of interval carcinomas after each scheduled screening session and detection of nonprogressive intraepithelial lesions has been termed "overdiagnosis." 29 In this study single genotype hrHPV infection was the most common pattern in both CIN 2/3 (69%) and CxCa cases (78%). The rates of detection of multiple HPV genotypes were mostly similar with use of the two test methods, although the rate of detection of more than three hrHPV infections was slightly higher using the Tellgen method than that using the YanengBIO method. It has been previously noted that estimating the fraction of CxCa attributable to different types is increasingly complicated by multiple infections in CxCa. In this study we also analyzed available Pap test data in patients with both extended hrHPV genotype testing and Pap test results at WCSUH. Interestingly, the Pap-negative rate of 4.3% was lower than the hrHPV-negative rate of 10.1% in 1094 patients with histopathologic CIN 2/3 diagnoses cotest results at WCSUH within the prior 6 months ( Table 7) . In 161 patients with histopathologic CxCa diagnoses and prior extended hrHPV genotyping and Pap cotest results within 6 months at WCSUH, the Pap-negative rate was 15.5% and the hrHPV-negative rate was 12.4% (Table 8) . Because verification bias inflates apparent screening test sensitivity in clinical datasets, verification bias-adjusted sensitivity for both screening tests are probably even lower than these figures indicate. 30 In the largest available Chinese study on cotesting prior to CxCa diagnosis, 238 Shanghai patients with CxCa and Pap and HPV cotesting within 1 year prior to diagnosis had an hrHPV-negative rate using the Hybrid Capture 2 HPV test of 15.5%, a Pap-negative rate of 15.5%, and a Pap and HPV-"double-negative" rate of 3.9%. 31 In other large Chinese studies on cotesting within 1 year of CxCa diagnosis, 155 Guangzhou CxCa cases had a Pap-negative rate of 1.9%, an HPV-negative rate of 9.7%, and a Pap and HPVdouble-negative rate of less than 1%, 32 and 78 Beijing CxCa cases had a Pap-negative rate of 11.5%, an HPV-negative rate of 10.3%, and a Pap and HPV-double-negative rate of 1.2%. 33 In contrast to these Chinese cotesting studies of populations with very limited prior screening, US cotesting takes place in a population largely undergoing routine periodic screening. In the largest US cotesting study, 600 Kaiser Permanente Northern California CxCa cases with Pap and HPV cotesting within 1 year of diagnosis reported a Papnegative rate of 13.7%, an HPV-negative rate of 9.8%, and a Pap and HPV-double-negative rate of 3.8%. 34 Despite differences between these studies, all reported significant HPVnegative rates and the lowest screening test false-negative rates utilizing Pap and HPV cotesting. The limitation of the current study is perhaps the fact that only cases with prior HPV test results within 6 months before histopathologic diagnoses of CIN 2/3 or CxCa were included, and a selective bias of HPV test and Pap test based on clinical judgment and the preference of the patients could exist.
Extended HPV genotyping is increasing in cervical screening outside the United States, where no FDAapproved extended genotyping tests are currently available. The logical utility of extended HPV genotyping is based on studies that have shown that persistent infections with highrisk genotypes are the predominant cause of CxCa and its potentially progressive precursor lesions. 10, 11 The present study showed little utility for routine lrHPV genotype testing. The data do support the utility of Pap and HPV cotesting for maximum protection against false-negative cervical screening test results in women developing CxCa. This study also confirms previous studies, which have shown that cervical screening is less efficacious for detecting and preventing cervical glandular neoplasia. 31, 35 (Extended HPV genotyping testing for persistent high-risk genotypes could theoretically aid in the early diagnosis of cervical glandular neoplasia, 36, 37 which is associated with both higher negative cytology and negative HPV rates than squamous cervical neoplasia. 
